Search Results - "NATHAN, STEVEN"

Progress in the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease by Nathan, Steven D

“…Pulmonary hypertension, frequently complicating the course of patients with fibrotic interstitial lung disease, is associated with significantly increased…”
Get full text

Reply to Jin et al .: Inhaled Treprostinil after Initial Clinical Worsening: To Continue or Not to Continue, That's the Question by Nathan, Steven D

“…Nathan responds to comments from Jin et al regarding his study on whether to continue or not the use of inhaled treprostinil for pulmonary veno-occlusive…”
Get full text

Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities by King, Christopher S, Dr, Nathan, Steven D, Prof

“…Summary Despite the development of pharmacological therapies that are effective in slowing the progression of idiopathic pulmonary fibrosis (IPF), it remains a…”
Get full text

Pulmonary hypertension in chronic lung disease and hypoxia by Nathan, Steven D, Barbera, Joan A, Gaine, Sean P, Harari, Sergio, Martinez, Fernando J, Olschewski, Horst, Olsson, Karen M, Peacock, Andrew J, Pepke-Zaba, Joanna, Provencher, Steeve, Weissmann, Norbert, Seeger, Werner

“…Pulmonary hypertension (PH) frequently complicates the course of patients with various forms of chronic lung disease (CLD). CLD-associated PH (CLD-PH) is…”
Get full text

Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease by Waxman, Aaron, Restrepo-Jaramillo, Ricardo, Thenappan, Thenappan, Ravichandran, Ashwin, Engel, Peter, Bajwa, Abubakr, Allen, Roblee, Feldman, Jeremy, Argula, Rahul, Smith, Peter, Rollins, Kristan, Deng, Chunqin, Peterson, Leigh, Bell, Heidi, Tapson, Victor, Nathan, Steven D

“…Patients with pulmonary hypertension due to interstitial lung disease were randomly assigned to inhaled treprostinil or placebo. At 16 weeks, there was a…”
Get full text

POINT: Should Every Patient With Idiopathic Pulmonary Fibrosis Be Referred for Transplant Evaluation? Yes by Nathan, Steven D.

Get full text

Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. Echoes of the Past, Lessons for the Future by Nathan, Steven D

“…Nathan reflects on the study by Behr and colleagues on the INSTAGE cohort, categorized by the presence or absence of echocardiographic evidence of right heart…”
Get full text

Rebuttal From Dr Nathan by Nathan, Steven D.

Get full text

Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment by Behr, Jürgen, Nathan, Steven D.

“…Purpose of review Pulmonary vascular disease resulting in pulmonary hypertension in the context of interstitial lung disease (PH-ILD) is a common complication…”
Get full text

High-Flow Nasal Cannula Therapy in COVID-19: Using the ROX Index to Predict Success by Chandel, Abhimanyu, Patolia, Saloni, Brown, A Whitney, Collins, A Claire, Sahjwani, Dhwani, Khangoora, Vikramjit, Cameron, Paula C, Desai, Mehul, Kasarabada, Aditya, Kilcullen, Jack K, Nathan, Steven D, King, Christopher S

“…Optimal timing of mechanical ventilation in COVID-19 is uncertain. We sought to evaluate outcomes of delayed intubation and examine the ROX index (ie,…”
Get full text

Inhaled Treprostinil in Group 3 Pulmonary Hypertension. Reply by Nathan, Steven D, Waxman, Aaron, Tapson, Victor

Get full text

The Value and Application of the 6-Minute-Walk Test in Idiopathic Pulmonary Fibrosis by Brown, A Whitney, Nathan, Steven D

“…The 6-minute-walk test is a commonly used assessment of performance ability in a variety of cardiopulmonary diseases. It provides important functional…”
Get full text

Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs by Zhang, Mingjun, Haughey, Michael, Wang, Nai-Yu, Blease, Kate, Kapoun, Ann M, Couto, Suzana, Belka, Igor, Hoey, Timothy, Groza, Matthew, Hartke, James, Bennett, Brydon, Cain, Jennifer, Gurney, Austin, Benish, Brent, Castiglioni, Paola, Drew, Clifton, Lachowicz, Jean, Carayannopoulos, Leon, Nathan, Steven D, Distler, Jorg, Brenner, David A, Hariharan, Kandasamy, Cho, Ho, Xie, Weilin

“…The Wnt/β-catenin signaling pathway has been implicated in human proliferative diseases such as cancer and fibrosis. The functions of β-catenin and several…”
Get full text

Response to: Derivation and validation of a noninvasive prediction tool to identify pulmonary hypertension in patients with IPF: Evolution of the model FORD by Nathan, Steven D., Kim, Ho Cheol, Chandel, Abhimanyu

Get full text

Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial by Nathan, Steven D, Tapson, Victor F, Elwing, Jean, Rischard, Franz, Mehta, Jinesh, Shapiro, Shelley, Shen, Eric, Deng, Chunqin, Smith, Peter, Waxman, Aaron

“…The INCREASE study of inhaled treprostinil met its primary endpoint of change in 6-minute-walk distance at Week 16. In addition, there were significantly fewer…”
Get full text

Long-term Course and Prognosis of Idiopathic Pulmonary Fibrosis in the New Millennium by Nathan, Steven D., MD, FCCP, Shlobin, Oksana A., MD, FCCP, Weir, Nargues, MD, FCCP, Ahmad, Shahzad, MD, Kaldjob, Julienne M., MD, Battle, Edwinia, RN, Sheridan, Michael J., ScD, du Bois, Roland M., MD

“…The American Thoracic Society and European Respiratory Society guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis (IPF) have been…”
Get full text

Lung Transplantation for Patients With COVID-19 by King, Christopher S., Mannem, Hannah, Kukreja, Jasleen, Aryal, Shambhu, Tang, Daniel, Singer, Jonathan P., Bharat, Ankit, Behr, Juergen, Nathan, Steven D.

“…The COVID-19 pandemic has caused acute lung injury in millions of individuals worldwide. Some patients develop COVID-related acute respiratory distress…”
Get full text

Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial by RAGHU, Ganesh, BEHR, Juergen, COSTABEL, Ulrich, RICHELDI, Luca, DE ANDRADE, Joao, KHALIL, Nasreen, MORRISON, Lake D, LEDERER, David J, LIXIN SHAO, XIAOMING LI, PEDERSEN, Patty S, MONTGOMERY, A. Bruce, BROWN, Kevin K, CHIEN, Jason W, O'RIORDAN, Thomas G, EGAN, Jim J, KAWUT, Steven M, FLAHERTY, Kevin R, MARTINEZ, Fernando J, NATHAN, Steven D, WELLS, Athol U, COLLARD, Harold R

“…Idiopathic pulmonary fibrosis (IPF) is characterized by formation and proliferation of fibroblast foci. Endothelin-1 induces lung fibroblast proliferation and…”
Get full text

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials by Noble, Paul W, Albera, Carlo, Bradford, Williamson Z, Costabel, Ulrich, du Bois, Roland M, Fagan, Elizabeth A, Fishman, Robert S, Glaspole, Ian, Glassberg, Marilyn K, Lancaster, Lisa, Lederer, David J, Leff, Jonathan A, Nathan, Steven D, Pereira, Carlos A, Swigris, Jeffrey J, Valeyre, Dominique, King, Jr, Talmadge E

“…Pirfenidone is an antifibrotic agent that has been evaluated in three multinational phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF). We…”
Get full text

The Future of Lung Transplantation by Nathan, Steven D., MD, FCCP

“…Lung transplantation has been the last of the solid organs to gain traction as a viable therapeutic option. Due to differing standards of care and the…”
Get full text